Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.

Publication Type:

Journal Article

Source:

The oncologist, Volume 19, Issue 8, p.892-9 (2014)

Keywords:

2014, August 2014, Public Health Sciences Division

Abstract:

The objective of this study was to investigate clinical effectiveness and incremental lifetime costs associated with first-line bevacizumab in older patients with metastatic colorectal cancer (mCRC).